Compare Boston Scientific Corporation (BSX) vs YieldMax Universe Fund of Option Income ETFs (YMAX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Boston Scientific Corporation vs YieldMax Universe Fund of Option Income ETFs — how do they compare? Boston Scientific Corporation trades at $42.62 (market cap $66.37B), while YieldMax Universe Fund of Option Income ETFs trades at $7.85. Which is the better fit depends on your goals.
| BSX | YMAX | |
|---|---|---|
Market Cap | $66.37B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $108.14 | $14.00 |
52-Week Low | $42.63 | $7.51 |
Enterprise Value | $75.94B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Boston Scientific (BSX) trades at $44.65, down 0.27% with bearish technical signals despite strong fundamentals. The company delivered three consecutive earnings beats with Q3-Q1 2026 EPS exceeding expectations, while revenue grew to $20.07B in 2025 with improving profit margins. Technical indicators show bearish momentum with support at $44 and resistance at $45, though Wall Street maintains 88% buy rating with $70.20 consensus target.
BSX presents a compelling value opportunity with attractive valuation multiples (P/E 18.68, P/S 3.24) and robust financial health, though near-term headwinds include competitive pressures in key segments and recent stock price decline of nearly 60% from 2025 highs. The strong analyst consensus suggests significant upside potential if execution improves.
YMAX trades at $7.82, down 1.26% today amid bearish technical signals with 16 sell indicators versus 1 buy. The ETF maintains weekly dividend distributions but faces scrutiny over its fund-of-funds structure and 1.33% fee. Recent articles highlight shrinking payouts and cost concerns, while technical analysis shows all moving averages signaling bearish momentum with neutral oscillators.
The outlook remains cautious as high fees and declining distributions pressure investor returns. Key risks include structural costs eroding yields and bearish technical momentum. Investment opportunity hinges on volatility-driven income generation, but current sentiment suggests limited upside without improved cost efficiency or market conditions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Boston Scientific Corporation
Boston Scientific produces less invasive medical devices that are inserted into the human body through small openings or cuts. It manufactures products for use in angioplasty, blood clot filtration, cardiac rhythm management, catheter-directed ultrasound imaging, structural heart disease, upper gastrointestinal tract diagnostics, interventional oncology, and treatment of incontinence. The firm markets its devices to healthcare professionals and institutions globally. Foreign sales account for nearly half of the firm's total sales.
Read more on BSX →About YieldMax Universe Fund of Option Income ETFs
YMAX is an actively managed 'fund of funds' that provides equal-weighted exposure to the full suite of YieldMax option income ETFs. It is designed to generate high current income by aggregating the premiums from various single-stock and thematic covered call strategies, offering a diversified approach to high-yield option investing.
Read more on YMAX →
